Imatinib mesylate-induced generalized hypopigmentation in patients with chronic myeloid leukemia

Sunita¹, DK Gupta¹, S Saluja², S Bhasin¹, M Sharma²,  
¹ Departments of Medicine, VMMC and Safdarjung Hospital, New Delhi 26166443, India
² Departments of Hematology, VMMC and Safdarjung Hospital, New Delhi 26166443, India

Correspondence Address:
Sunita
Departments of Medicine, VMMC and Safdarjung Hospital, New Delhi 26166443
India

Full Text

Imatinib mesylate (STI-571) is a recently developed oral anticancer agent rationally designed to selectively inhibit certain protein kinases implicated in the pathogenesis of chronic myeloid leukemia (CML) and malignant gastrointestinal stromal tumors.[1] Imatinib mesylate inhibits the bcr-abl tyrosine kinase, thus blocking proliferation and growth of tumor cells expressing bcr-abl. It is generally well tolerated and most side effects are mild to moderate in severity. The common side effects are edema, nausea, vomiting, diarrhea, muscle cramps, and cutaneous reactions. Serious side effects such as hepatotoxicity and myelosuppression also occur, warranting regular monitoring and interruption of treatment.[2] The common dermatological side effects are periorbital edema and dermatitis. Facial edema, pruritis, erythema, dry skin, alopecia, night sweats, and photosensitivity reactions are infrequently reported.[3] We are highlighting an interesting dermatological effect, generalized hypopigmentation, as a result of imatinib therapy, noticeable especially in Indian population because of the dark complexion.

A retrospective analysis of 15 patients of CML on imatinib mesylate between Sept 2003 and Sept 2004 was carried out. Imatinib mesylate was started as first-line therapy in five patients. In the remaining 10 patients, the drug was initiated when therapy with hydroxyurea and interferon did not show evidence of hematologic and cytogenetic response. Imatinib mesylate was initiated during the chronic phase of CML in eleven, accelerated phase in one, and blast crisis in three patients. The dose of imatinib was 400 mg/day in the chronic phase and 600 mg/day in the accelerated and blast crisis phases.

After initiation of the drug, patients were followed weekly for 1 month and thereafter every 2 weeks for an average of 15 months (range: 8-23 months). No patient was lost to follow up. During each visit, patients were assessed for constitutional symptoms, weight gain, periorbital edema, jaundice, vomiting, and diarrhea. Hemogram was done during each visit and liver function tests were done monthly. Bone marrow aspiration was done after 6 months of initiation of drug to assess the cytogenetic response. Complete hematological response was defined as disappearance of signs and symptoms of disease, no splenomegaly, and normal blood counts (TLC P C -kit receptor tyrosine kinase. The last two kinases have critical roles in normal pigmentation. Mutation in these genes, reducing or abrogating the respective enzyme activities, are associated with loss of pigmentation owing to interruption of the development and differentiation of melanocytes. Imatinib produces a similar effect by inhibition of the crucial kinases. Rapid clearance of hydroxyurea from the hyperpigmented skin in four patients who had received the drug as the first-line therapy superimposed by decreased production of melanin as a result of initiation of imatinib mesylate led to a more dramatic effect in this group of patients. Hydroxyurea is a drug known to cause hyperpigmentation of skin and soft tissues. Review of literature revealed few case reports of imatinib-induced patchy as well as generalized hypopigmentation.[1],[3] Adverse effects arising from skin hypopigmentation include photosensitivity, which is resolved using a sun-screen and avoidance of sun exposure.[4]

In conclusion, we highlight an interesting dermatological effect-the generalized hypopigmentation, owing to imatinib mesylate that was noticed in 80% of our patients of CML. Although a cosmetic problem, it does not pose a substantial medical hazard and does not appear to predict the leukemic cell response or clinical outcome.

References